Recent reports suggest that a CD20‐negative phenotypic change occurs in a certain number (approximately 26.3%) of CD20‐positive B‐cell lymphoma patients after rituximab‐based treatment.17 The gene discussed is MS4A1; the disease is B-cell non-Hodgkin lymphoma.